Breaking News

MindMed Partners with Catalent on its Zydis Technology

Provides MindMed with exclusive rights to use the Zydis technology to develop all salt and polymorphic forms of lysergide.

MindMed, biopharmaceutical company developing novel candidates to treat brain health disorders, has entered into a license agreement with Catalent to access Catalent’s Zydis orally disintegrating tablet (ODT) technology for the development of MindMed’s lead product candidate MM-120 (lysergide D-tartrate), a pharmaceutically optimized form of lysergide. The agreement also provides MindMed exclusive rights to use the Zydis technology to develop all salt and polymorphic forms of lysergide in the...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters